Biovail Corporation, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products used in the treatment of specialty central nervous system disorders. Its product portfolio includes Wellbutrin XL for the treatment of depression in adults; Xenazine for the treatment of chorea associated with Huntington's disease; Aplenzin for the treatment of major depressive disorder; Zovirax Ointment for the management of initial genital herpes; Zovirax Cream for the treatment of herpes labialis; Ultram ER for the management of chronic pain in adults; and Cardizem LA that provides blood pressure control. The company also provides Tiazac/Tiazac XC for the treatment of hypertension and angina; Wellbutrin SR for the treatment of depression; Glumetza for the control of hyperglycemia in adult patients with type 2 diabetes; Ralivia for the management of pain of moderate severity; Nitoman for the treatment of hyperkinetic movement disorders; Cardizem CD medications in the calcium channel blocker category of cardiovascular drugs; and Zyban for smoking cessation treatment. In addition, it distributes various other pharmaceutical products, including Ativan for the management of anxiety disorders; Vasotec and Vaseretic for the treatment of hypertension, symptomatic congestive heart failure, and asymptomatic left ventricular dysfunction; and Isordil to treat prophylaxis of ischemic heart pain associated with coronary insufficiency. The company?s generic products consist of bioequivalent formulations of Cardizem CD, Adalat CC, Procardia XL, Tiazac, Voltaren XR, and Trental. In addition, it offers research, development, and clinical contract research services to third parties. The company distributes its products primarily through third party commercialization relationships in the United States and Canada. Biovail Corporation was founded in 1983 and is headquartered in Mississauga, Canada.

Delcath Systems, Inc., a development stage company, develops and manufactures devices to administer high dose chemotherapy and other therapeutic agents directly to diseased organs or regions of the body. It focuses on the development of the Delcath PHP System, a Phase III clinical trial product, which isolates the liver from the patient?s general circulatory system and delivers high dose of melphalan hydrochloride or other therapeutic agents directly to the liver. The Delcath PHP System kit includes an arterial infusion catheter, a multi-passageway/double balloon catheter, a blood tubing filtration circuit, two hemoperfusion filters, a return catheter/a thin-walled blood sheath, and a series of introducers and related accessories to properly place the catheters. The company also conducts Phase II clinical trials to test the Delcath PHP System with melphalan against liver cancer, neuroendocrine tumors, hepatocellular carcinoma, ocular or cutaneous melanoma, and metastatic adenocarcinoma that have spread to the liver, and melanomas metastatic to the liver that have received prior regional treatment. It has a cooperative research and development agreement with the National Cancer Institute to develop and evaluate the Delcath PHP System device. Delcath Systems, Inc. was founded in 1988 and is based in New York, New York.